xMAP INSIGHTS ®
Assay Development Issue
For Rapid Assay Development in the Time of COVID, UNMC’s Emerging Pathogens Laboratory Uses xMAP® Technology Read more on page 8
Pictured: The Emerging Pathogens Laboratory Team at the University of Nebraska Medical Center
Page
6
Need a Hand? Ask Our Custom Assay Experts at the LuminexPLORE Lab
Page
10
Luminex Launches MagPlex® Monitoring Microspheres for xMAP® Assays
xMAP INSIGHTS ®
A Magazine for the Multiplexing Community Hello, Welcome to xMAP® Insights, the magazine written for xMAP Super Users. This issue highlights a variety of topics, including our new MagPlex® Monitoring Beads and a sneak peek into the LuminexPLORE Lab as it undergoes an overhaul. Here are just a few of the stories shared in this issue: • With the help of the LuminexPLORE lab team, Vor Biopharma checks guide RNAs using xMAP Technology. • Scientists at the University of Nebraska Medical Center used xMAP Technology to rapidly respond to the pandemic. • For xMAP newbies, the Luminex Learning Team provides training to kickstart your first xMAP project! I hope you enjoy this issue as much as I do. Please contact me directly at lkessler@luminexcorp.com with any future story ideas you might have. Thank you for being a member of our community. All the best,
Lisa Kessler, MBA Scientific Marketing Licensed Technologies Group Luminex Corporation
2
CONTENTS 2
Letter from the Editor
4
For Gene Editing, Vor Biopharma Checks Guide RNAs with xMAP® Technology
6
Need a Hand? Ask Our Custom Assay Experts at the LuminexPLORE Lab
8
For Rapid Assay Development in the Time of COVID, UNMC’s Emerging Pathogens Laboratory
Uses xMAP® Technology
10
Luminex Launches MagPlex® Monitoring Microspheres for xMAP® Assays
12
Want to Be an xMAP® Rock Star? Our Training Courses Can Help
14
xMAP® Connect Boston
For Gene Editing, Vor Biopharma Checks Guide RNAs with xMAP® Technology by Christina Olivas
One of the reasons xMAP® Technology is so widely used is its versatility. Multiplex bead-based assays can be used for genomic and proteomic queries across countless applications. This was a big part of why Vor Biopharma decided to use xMAP assays to replace a PCR-based gene editing workflow.
streamline the process of moving assays along the biopharma pipeline and into highly regulated downstream use.
Showing up during times of need
At the recent xMAP Connect user conference, Pete Cotter, Associate Director of Analytical Development at Vor, gave a presentation about how his team is using xMAP assays for cell and gene therapies— from early research and development to the characterization of drug products. The work began as a collaboration with the LuminexPLORE Lab, where our team of experts developed a custom assay to measure and quantify residual guide RNAs in drug product. Pete first encountered xMAP Technology at Massachusetts General Hospital around 2005. At the time, he and his colleagues used xMAP assays to generate more data from limited sample volumes. “We were really amazed with the data we could glean from these samples,” he said. Today, he works on cell and gene therapies for people diagnosed with hematological malignancies at Vor.
The outcome was just what Pete had hoped for. “We were really pleased with our collaboration with Luminex,” he said. The new workflow was at least an hour and a half shorter than their previous one, with possibilities for reducing it even more. Further, almost all steps take place on the thermocycler or FLEXMAP 3D® instrument, giving Vor “a faster readout with less operator time” compared to the previous technique. Also, results were highly sensitive and comparable across methods; the team even uses the same standard curve for the xMAP assay that they had been using for droplet digital PCR. “It was an extremely smooth transfer of this assay back into our shop,” Pete said.
Supporting better care through a streamlined workflow The standard of care for people with acute myeloid leukemia is a hematopoietic stem cell transplant. Unfortunately, in their natural state, these cells express many of the same biomarkers as cells targeted by AML therapeutics, which can lead to loss of the graft. At Vor, scientists aim to overcome this challenge by editing healthy donor hematopoietic stem cells to remove those targets, effectively “making them invisible bone marrow cells,” Pete shared. This allows the use of targeted therapies without risking loss of the donor cells, potentially paving the way for more people to experience true remission. As part of the editing process, Vor scientists need to detect and quantify residual guide RNA in drug product, a method they originally performed with droplet digital PCR. But that technique takes a full day and requires many different instruments, as well as substantial hands-on time to prepare and move samples. Because of this, Pete thought xMAP Technology might be a better option. Because it’s run on GMP-compliant platforms, it would
To get the process going, Pete reached out to the LuminexPLORE Lab team and they started developing an assay to target the variable region of the guide RNAs. Being able to rely on the custom assay service group was a win when Vor needed it—at the time, the pandemic had just started and Vor had outgrown its lab but needed time to build out a new facility. Together, scientists at Vor and Luminex mapped out a strategy. The Luminex team designed the oligo probe sequence and worked with an external oligo vendor for manufacturing. Then, using the manufactured probes, the LuminexPLORE Lab performed the proof-of-concept study and assay optimization, transferring the finished assay back to Vor as they moved into their new lab.
Going forward, Pete plans to expand the team’s use of xMAP Technology. Potential applications include identity confirmation for mRNA, nucleases, viruses, and growth factors, plus editing confirmation for known indels and genomic sequences. This approach could streamline assays currently performed on nextgeneration sequencing instruments, making those processes faster and less expensive. For additional inspiration or to learn how your team could get more from xMAP Technology, check out the xMAP Cookbook.
xMAP® INSIGHTS | Fall 2021 4
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Introducing xMAP INTELLIFLEX® The same xMAP® Technology you love, now designed to do more. xMAP INTELLIFLEX® is the first xMAP multiplexing platform that combines low- and high-plex capabilities, quick time to results, and the ability to get double the data per analyte with its new dual reporter capability.
It’s worth getting xCITED about. Learn more at luminexcorp.com/INTELLIFLEX.
For Research Use Only. Not for use in diagnostic procedures. ©2021 Luminex Corporation. A DiaSorin Company. All Rights reserved. Luminex and xMAP are trademarks of Luminex Corporation, registered in the US and other countries. xMAP INTELLIFLEX is a trademark of Luminex Corporation.
xMAP® INSIGHTS | Fall 2021 5
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Need a Hand? Ask Our Custom Assay Experts at the LuminexPLORE Lab by Lisa Kessler Sometimes, you just need a little extra support to take your research to the next level, and supporting our customers was just one of the many reasons why we launched the LuminexPLORE Lab—a custom assay services unit with expertise spanning everything from bead coupling and sample testing to assay development, conversion, and validation. Maybe you’ve designed a multiplex assay and you just can’t get it working. Or maybe you have plans for the perfect assay, but you can’t find the bandwidth to get the work done. Or maybe there’s no available kit to meet your needs. Whatever the challenge, our expert team of scientists is here to help!
"When we moved from one lab space to another, the technology couldn't wait. [It was the] perfect time to have LuminexPLORE lab do the proof-of-concept work.”
So when should you reach out to our custom services team? According to Sheri Calderon, Project Manager for the LuminexPLORE Lab, “anytime you’re not sure what the next step is, or if you have a hunch about what you want but can’t quite find the time to make it happen yourself.” She and her colleagues have been working in the industry for years and have extensive experience developing assays— expertise, she adds, “that really sets us apart from other custom services companies.” The LuminexPLORE Lab aims to serve customers wherever they are—whether that’s major biopharmaceutical companies, startup labs, academic or nonprofit institutions. Our team can help whether you’re an xMAP novice seeking proof-of-concept testing or a longtime user looking to optimize a sophisticated multiplex assay. Projects can be simple and quick, like custom coupling, or more robust, such as developing and manufacturing an assay. It really is up to you. To learn more about the LuminexPLORE Lab, reach out to your Luminex sales representative or field application scientists, or visit luminexcorp.com/luminexPLORE.
The LuminexPLORE Lab builds on the success of our custom assay services team, adding a brand-new lab facility and talented new team members to help meet the rapidly growing demand for custom projects. Our scientists have years of experience in areas ranging from biomarkers and cancer to immunology and toxicity, and they’ve worked in both academia and biotech. With their combined expertise in developing highly sophisticated genomic and proteomic assays based on our xMAP® Technology, there’s no project too big or too small to handle. How can the LuminexPLORE team make a difference for your research? Here are some of our core service options: • • • • • • •
Antibody pair screening Custom coupling Sample testing Custom assay development Assay optimization Assay conversion (e.g., switching from ELISA to an xMAP assay) Assay validation (precision, accuracy, lot-lot, scale-up, etc.)
“We want to be able to empower you to ask for help and equip you with the guidance or tools you need,” says Jackie Surls, PhD, Director of the LuminexPLORE Lab. “We can customize our services to meet your unique needs.”
To meet the demand for LuminexPLORE custom lab services, we needed more space and a bigger team. Our team of experts has already doubled in size and the new LuminexPLORE Lab space will be open early next year!
xMAP® INSIGHTS | Fall 2021 6
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
LuminexPLORE Lab
xMAP® Custom Assay Development Services LuminexPLORE Lab is a custom service program that uses industry-leading xMAP® Technology to offer researchers a competitive edge for scientific breakthroughs. Join our community of xMAP developers to accelerate your research. Available Services: • • • • • • •
Antibody pair screening Custom coupling Custom conjugation Sample testing Assay development Optimization of existing homebrew xMAP® assay Assay conversion
• Add-on assay validation options: - Precision (intra and inter) - Sensitivity (LoD) - Cross-reactivity - Lot-lot variability - Scale-up • Advanced applications for current users
Custom Services Workflow
Step 1
Step 2
Step 3
Submit a custom services request.
Consult with an Applications Scientist.
Luminex experts develop the assay.
Reach out today to LumineXPLORE@luminexcorp.com to consult with our Applications Scientists and see what xMAP® and xTAG® can do for you. For Research Use Only. Not for use in diagnostic procedures. ©2021 Luminex Corporation. A DiaSorin Company. All rights reserved. Luminex, xMAP, and xTAG are trademarks of Luminex Corporation, registered in the US and other countries.
For Rapid Assay Development in the Time of COVID, UNMC’s Emerging Pathogens Laboratory Uses xMAP® Technology by Heather Darby Scientists at the University of Nebraska Medical Center (UNMC) are among the world’s leading experts in infectious diseases. When the first Americans diagnosed with COVID-19 infections were brought back to the US after a cruise in Japan, they were sent to UNMC for quarantine and treatment. Not long after, researchers there responded to the pandemic by launching a new, cutting-edge lab to develop improved diagnostic assays for infectious disease analysis.
the range of a given lab’s specific needs. If a commercial assay only addresses 80 percent of the questions a healthcare provider might have, for example, “rapid assay development done by small teams like ours is how we find answers for the remaining 20 percent,” he says.
Together with Andy Schnaubelt, PhD, Jana Broadhurst, MD, PhD, DTM&H launched the Emerging Pathogens Laboratory in 2020, building on their expertise in infectious diseases, assay development, and regulatory requirements. “Something that has been a gap for a long time but was really highlighted by the COVID pandemic is the need for rapid translation of novel diagnostics into a clinical laboratory space that can support the dual needs of clinical testing as well as clinical research support,” she says. “It makes a lot of sense to have all of that diagnostic development happen under one roof.” To this end, Dr. Broadhurst’s team used xMAP® Technology to design a multiplex assay for detecting SARS-CoV-2 antibodies, which they developed and validated in a single week. “This is the real key—” Dr. Broadhurst explains, “being able to rapidly design, build, validate, and implement diagnostic tests.”
The Emerging Pathogens Laboratory team at the University of Nebraska Medical Center.
For emerging pathogen detection, flexibility is critical
Supporting testing needs as they evolve with xMAP Technology
The COVID-19 pandemic has been an unprecedented, real-world demonstration of how important rapid assay development is for managing infectious diseases. When labs shifted to support COVID research and diagnostics, speed, specificity, and the flexibility to iterate on demand became more important than ever. On the need for speed, “being able to adapt our laboratory testing technologies to detect what is going to be important for strain variants is a very clear example” Dr. Broadhurst adds.
Having control over the assay development process enables each lab to optimize an assay to cover a broad range of parameters based on evolving needs. “We don’t always receive a perfect sample,” Dr. Schnaubelt notes. “We have to be able to adjust parameters for the broadest applicability. There is no one-size-fits-all solution.”
She notes that there will always be a lag between the need for a new test and availability of it—that’s inescapable when dealing with emerging diseases—but waiting until the need exists to begin planning leads to unacceptably long delays. To manage the COVID-19 outbreak, her team aims to anticipate the next diagnostic need and work towards it before it arises. Staying ahead of the game means that relying on commercial diagnostic developers can set testing labs back in more ways than one. As Dr. Schnaubelt points out, once tests finally become commercially available, there’s still a chance they may not meet
Dr. Broadhurst and Dr. Schnaubelt cite the platform’s multiplexing capabilities, flexibility, throughput, speed, and ease of customization, as well as “the rich and deep literature describing the science, application, and customization [capabilities] of xMAP assays” as what gave their lab “a rock-solid launching point to begin our own assay design,” Dr. Schnaubelt says. And as a long-standing user of xMAP Technology, Dr. Broadhurst is familiar with our Field Application Scientists and Technical Support teams. “Working with Luminex was exceptional,” Dr. Schnaubelt says. “When we had questions, the Luminex Support team listened to our needs and provided immediate and relevant help.” xMAP® INSIGHTS | Fall 2021
8
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
NEW HUMAN METABOLIC LUMINEX PERFORMANCE ASSAY Accelerate your metabolic research forward with the new Human Metabolic Luminex Performance Assay from R&D Systems. Designed to detect multiple metabolic biomarkers and get you reliable results faster. Panel features include: • Rigorous quality control testing for consistent, reliable performance • Optimized assay diluents to eliminate false positive data • No overnight incubation period so you get your results faster • Customizable panel with 12 metabolic biomarkers to select from
View the data | bio-techne.com/reagents/luminex-assays/metabolic-panel
xMAP® INSIGHTS | Fall 2021
bio-techne.com
Global info@bio-techne.com bio-techne.com/find-us/distributors TEL +1 612 379 2956 North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449 China info.cn@bio-techne.com TEL +86 (21) 52380373
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
9
For research use or manufacturing purposes only. Trademarks and registered trademarks are the property of their respective owners.
Luminex Launches MagPlex® Monitoring Microspheres for xMAP® Assays by Gabby Mora
We’re pleased to announce we’ve added an important new tool for Luminex customers to our xMAP® portfolio: MagPlex® Monitoring Microspheres! These monitoring beads make it possible to assess reporter values and reporter channel performance in every well, and are especially helpful during assay development.
interested in monitoring assay performance. They can help users troubleshoot unexpected MFI patterns, weak signals, and other issues that may arise.
Luminex Senior Field Application Scientist Stephen Angeloni, PhD, has worked with a pre-commercial version of this product for years. “It’s very handy to have these beads in the reaction so if a problem does arise, you can quickly identify whether it’s on the instrument side or the assay side,” he shares. “They’re useful for quality control in an assay, and are particularly helpful for new users of xMAP systems,” he adds. Stephen has used these beads to help customers who had technical challenges with their assays, such as weak signals or unexpected fluorescence patterns. Adding monitoring beads made it easier to troubleshoot the cause of those issues. With the added quality control these beads provided, he was able to identify common culprits in many assay development workflows, including reagents that have degraded over time, forgotten detection reagents, and inaccurate pipette volumes.
“It’s very handy to have these beads in the reaction so if a problem does arise, you can quickly identify whether it’s on the instrument side or the assay side.” “The benefits of these beads also extend to assay kits that are being used at different sites,” Stephen adds. “It’s important to have a control element to ensure that an assay and instruments are performing the same at all sites—these beads can help with that.” These microspheres are also a great fit for Luminex Partners developing new xMAP-based assays.
The decision to launch the beads as a standalone product was influenced in part by the release of the new xMAP INTELLIFLEX® System. With the development of the dual reporter channel—and the need to clearly distinguish which channel each data point comes from—these beads can provide a valuable extra layer of information. “Having these beads in your assay can tell you right away if you’re looking at data from the RP1 or RP2 channel,” Stephen says. The beads are magnetic polystyrene microspheres that have been color-coded for classification in regions 45 or 222, and provide reporter MFI values specific to instrument type and reporter modes. The reporter dyes are inside the beads rather than on the surface, so there is no modification necessary to use them in your regular xMAP workflow. They can simply be combined with the other beads needed for an assay. Two MagPlex Monitoring Microspheres are available corresponding to the reporter channel being monitored: MagPlex RP1 Monitor beads (Region 45), which are compatible with all xMAP instruments, including the MAGPIX®, Luminex® 200TM, FLEXMAP 3D®, xMAP INTELLIFLEX®, and xMAP INTELLIFLEX® DR-SE systems; and MagPlex RP2 Monitor beads (Region 222), which are only compatible with the xMAP INTELLIFLEX DR-SE System. As a note, MagPlex Monitoring Microspheres require xPONENT® or xMAP INTELLIFLEX software. Like all things xMAP, the inclusion of these monitoring beads can lead to additional time and resource savings—but don’t just take our word for it, check out other multiplexing applications in our publications database from xMAP users across the world!
Empowering xMAP users to get answers when they need them In the past, monitoring beads were a great tool for helping xMAP users who sought out assay development support from our experts. Now, as a commercially available product, these microspheres will be more widely available, offering a valuable resource to anyone
xMAP® INSIGHTS | Fall 2021 10
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
xMAP® INSIGHTS | Fall 2021 11
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Want to Be an xMAP®Rock Star? Our Training Courses Can Help by Lisa Kessler
Here are some of the things you can expect to cover in our training classes:
As developers of xMAP® Technology, we’re passionate about empowering researchers to get the most out of their xMAP-based platforms and assays. We design our products and software tools to be as intuitive and easy-to-use as possible, but we also offer various kinds of training and technical support courses for new and veteran users alike, supporting everything from streamlining your assay and mastering a new skill to automating your workflow and upgrading your platform.
Instrument Session(s) • Learn how to develop an assay and perform a mock assay run • Understand instrument components • Learn basic commands and routines in xPONENT® Software • Analyze data and export results
Luminex Learning through the years
Assay Session(s) (available for proteomic or nucleic acid assays) • Determine the appropriate assay format for various applications • Learn the coupling procedure • Learn the basics of assay optimization • Analyze data in xPONENT® Software
For years, our Technical Training group has hosted Learning Sessions, providing our users with tips and tricks from our experts on how to get the most out of our instruments and assays. With the COVID-19 pandemic and the resulting lockdowns, we quickly shifted to virtual training, fine-tuning our courses to create remote program options.
For these classes, the Technical Training team recommends that attendees have some basic familiarity with their Luminex instrument as well as regular access to it so they can practice their new skills after they complete the course. For virtual classes, we encourage attendees to sign in using a device with a microphone to make it easier to ask questions.
This led to an engaging, multi-day training course featuring a variety of approaches, including presentations, step-by-step demonstrations, and a live Q&A session with our scientists. “It’s like a cooking showstyle class where we demonstrate how to do everything,” says Terrin Blackmon, Senior Technical Training Coordinator at Luminex.
To learn more about Luminex Learning classes, view the schedule, or get in touch to find out about costs or availability, check out our website: luminexcorp.com/luminex-learning-sessions.
Whether you’re designing your own assays or running off-the-shelf xMAP assays from our partners, you can count on us to ensure you have the technical knowledge you need.
These virtual courses have provided accessibility and flexibility for our community, so we plan to continue offering them well into next year (and beyond). We also intend to resume in-person Luminex Learning Sessions once it is safe and feasible to do so.
Supporting learning through bi-annual workshops We host workshops at least twice each year, with courses that cover xMAP instruments (Luminex® 200™, MAGPIX®, and FLEXMAP 3D®) as well as assay development. Additionally, we run each course for five days, enabling our users to build a training schedule that makes sense for their lab. “This way users can pick and choose based on what they need,” Terrin says. “Maybe there’s a new person in the lab who needs to get up to speed on basic operations, or maybe someone wants insight into the principles of assay development.”
Rachel Wypych leads a class on the Luminex® 200TM System
xMAP® INSIGHTS | Fall 2021 12
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Quickly assay neutralizing antibodies to wild-type and variant SARS-CoV-2 RBD and S1 antigens.
#ScienceForward
Quantify neutralizing antibodies against SARS-CoV-2 variants Rapidly quantitate neutralizing antibodies against wild-type SARS-CoV-2 and variants using the Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody 11-Plex Panel (for research use only). Assess the efficacy of COVID-19 vaccines and monoclonal antibody therapeutics or compare the effectiveness of antibody responses to emerging variants of concern. Screen all or select variants of interest or concern with the panel’s flexible design. xMAP® INSIGHTS | Fall 2021
13
See performance data at bio-rad.com/BioPlexNAbAssayPerformance Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
BOSTON
We were so grateful to meet with our colleagues and xMAP® users! Looking forward to seeing you at the next regional xMAP event. Check out our archived xMAP Connect presentations here.
Hallmarks of Cancer Now Invitrogen ™ ProcartaPlex™ protein assays offer researchers a quick and reliable way to address the hallmarks of cancer from cell proliferation
and metastasis, resisting cell death, evading immune destruction, to even exosome characterization. This expanded menu of protein markers offers the largest selection and flexibility to customize panels of choice for any cancer research needs. Choose from preconfigured panels or design your own Mix & Match Oncology panel using the ProcartaPlex Panel Configurator..
Learn more at: thermofisher.com/procartaplex
On-Demand Webinar presented at Cancer Research & Oncology 2021 Sponsored by Luminex Corp
Uncover All Hallmarks of Cancer with Multiplex Gene and Protein Assays Using Luminex Technology Learn about Invitrogen Quantigene RNA assays and ProcartaPlex
Click here to view the on-demand webinar
Thermo Fisher Scientific Laboratory Automation solutions include automated incubators, configurable platforms, robotic movers, workflow scheduling software, and lab informatics. Customizable setups and concepts are now available for our Invitrogen™ QuantiGene Plex and ProcartaPlex assays. The Thermo Fisher Laboratory Automation team brings decades of experience in automated incubation, laboratory robotics and workflow scheduling. Our dedicated team of specialists is on-hand to provide automation support and expertise to meet your laboratory high-throughput needs, now also for xMAP-based multiplex assays. Scalable solutions from single step liquid transfers to full systems that also include reagent dispensing, plate sealing and peeling, and magnetic bead washing, are available. Solutions are also available for multiple throughputs ranging from partial plates to multiple plates within the same run. Find out more at: Thermofisher.com/Luminex 15
For Research Use Only. Not for use in diagnostic procedures
xMAP® INSIGHTS | Fall 2021
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Plex Your Primate Studies New MILLIPLEX® Non-Human Primate Multiplex Panel For cytokine and growth factor research, nonhuman primates are critical in gaining more insights into the immune system since they are the most closely related species to humans. Our new multiplex panel, the MILLIPLEX® Non-Human Primate Cytokine/Chemokine/ Growth Factor Panel A, offers more analytes in one easy-to-use kit.
Benefits of MILLIPLEX® Non-Human Primate Panel A: Flexible: Choose any combination of analytes, customize your premix, or select a 38-plex or 48-plex premixed kit Verified: Fully verified in serum and plasma from two commonly used non-human primate species, rhesus and cynomolgus macaques User-Friendly: Reduce variability with ready-to-use reagents and a straightforward protocol Streamlined: No need to mix and dilute multiple reagents prior to assay set-up Explore our new non-human primate multiplex panels to obtain reproducible results in less time.
Discover more at SigmaAldrich.com/milliplex-primate
© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M and Millipore are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.
37265 08/2021
16
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
xMAP® INSIGHTS | Fall 2021 Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
xMAP INSIGHTS ®
Looking for even more xMAP® content? Subscribe to the xMAP Resource Round-Up, and don't forget to check out this year's xMAP Connect!
©2021 Luminex Corporation. A DiaSorin Company. All Rights Reserved. Luminex, xMAP, xPONENT, FLEXMAP 3D, MAGPIX, MagPlex, and xTAG, and xMAP INTELLIFLEX are trademarks of Luminex Corporation, registered in the US and other countries. Luminex 200 is a trademark of Luminex Corporation. All other trademarks are property of their respective owners. luminexcorp.com
Luminex xMAP Insights | June 2018 | Luminex supports life science research with its Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
